{"id":"ketoconazole-tablet","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Liver function abnormalities"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL295698","moleculeType":"Small molecule","molecularWeight":"531.44"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting lanosterol 14α-demethylase, ketoconazole disrupts the integrity of the fungal cell membrane, leading to cell death. It also has some anti-androgenic effects due to its inhibition of steroidogenesis.","oneSentence":"Ketoconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a vital component of fungal cell membranes, by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:01.035Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of systemic fungal infections such as blastomycosis, coccidioidomycosis, histoplasmosis, and aspergillosis"}]},"trialDetails":[{"nctId":"NCT03907046","phase":"PHASE3","title":"Anticoagulation in ICH Survivors for Stroke Prevention and Recovery","status":"RECRUITING","sponsor":"Yale University","startDate":"2020-01-28","conditions":"Intracerebral Hemorrhage, Atrial Fibrillation","enrollment":700},{"nctId":"NCT04869449","phase":"EARLY_PHASE1","title":"Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2022-05-11","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain","enrollment":1},{"nctId":"NCT04037605","phase":"EARLY_PHASE1","title":"Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2020-02-09","conditions":"Sleep Restriction","enrollment":5},{"nctId":"NCT02618577","phase":"PHASE3","title":"Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes","status":"TERMINATED","sponsor":"Atrial Fibrillation Network","startDate":"2016-02","conditions":"Atrial High Rate Episodes","enrollment":2608},{"nctId":"NCT03763396","phase":"EARLY_PHASE1","title":"Azoles Targeting Recurrent High Grade Gliomas","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2024-06-01","conditions":"Brain Tumor, Recurrent, Cancer, Advanced, Glioma of Brain","enrollment":30},{"nctId":"NCT01323465","phase":"PHASE1","title":"Study to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2008-02","conditions":"Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Known Inducer of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4, Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a CYP2C19 Inhibitor","enrollment":36},{"nctId":"NCT03277690","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.","status":"COMPLETED","sponsor":"Cortendo AB","startDate":"2017-09-26","conditions":"Endogenous Cushing's Syndrome","enrollment":84},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT02163356","phase":"PHASE1","title":"Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma","status":"TERMINATED","sponsor":"South Plains Oncology Consortium","startDate":"2014-05","conditions":"Recurrent Neuroblastoma, Neuroblastoma","enrollment":4},{"nctId":"NCT01838551","phase":"PHASE3","title":"Treatment for Endogenous Cushing's Syndrome","status":"COMPLETED","sponsor":"Cortendo AB","startDate":"2014-08","conditions":"Endogenous Cushing's Syndrome","enrollment":94},{"nctId":"NCT03261336","phase":"PHASE2","title":"Oral Calcitriol With Ketoconazole in CRPC","status":"TERMINATED","sponsor":"Donald Trump, MD","startDate":"2017-01-06","conditions":"Castration-resistant Prostate Cancer","enrollment":1},{"nctId":"NCT04212000","phase":"PHASE1","title":"Bioavailability of Levoketoconazole and Ketoconazole Tablets","status":"COMPLETED","sponsor":"Cortendo AB","startDate":"2019-12-16","conditions":"Healthy","enrollment":34},{"nctId":"NCT01896323","phase":"PHASE1","title":"CC-223 and Ketoconazole Drug-Drug Interaction Study","status":"COMPLETED","sponsor":"Celgene","startDate":"2013-07-01","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT01707407","phase":"PHASE1","title":"A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects","status":"COMPLETED","sponsor":"Celgene","startDate":"2012-09-01","conditions":"Pharmacology, Clinical, Healthy","enrollment":32},{"nctId":"NCT01448824","phase":"PHASE1","title":"A Study of LY2484595 on Pharmacokinetics in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-10","conditions":"Healthy Participants","enrollment":82},{"nctId":"NCT00659555","phase":"PHASE1","title":"Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-04","conditions":"Macular Degeneration","enrollment":24},{"nctId":"NCT01454076","phase":"PHASE1","title":"Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2011-11-10","conditions":"Nonhematologic Malignancies, Lymphoma","enrollment":112},{"nctId":"NCT00404378","phase":"PHASE1","title":"Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-20","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":15},{"nctId":"NCT00460707","phase":"PHASE1","title":"A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-16","conditions":"Nausea and Vomiting, Chemotherapy-Induced","enrollment":85},{"nctId":"NCT00411866","phase":"PHASE1","title":"Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-13","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT01165125","phase":"PHASE1","title":"A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Asthma","enrollment":18},{"nctId":"NCT01787032","phase":"PHASE1","title":"Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT01240226","phase":"PHASE1","title":"A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-11","conditions":"Healthy Volunteer","enrollment":22},{"nctId":"NCT00680485","phase":"PHASE1","title":"Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Bacterial Infection, Infections, Bacterial","enrollment":96},{"nctId":"NCT00388557","phase":"PHASE1","title":"Effect of Ketoconazole on the Pharmacokinetics of Vinflunine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-10","conditions":"Cancer","enrollment":35},{"nctId":"NCT01267084","phase":"PHASE1, PHASE2","title":"A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-02","conditions":"Neoplasm Metastases","enrollment":12},{"nctId":"NCT01735240","phase":"PHASE1","title":"Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-12","conditions":"Asthma,, Pharmacokinetics,, Cmax,","enrollment":15},{"nctId":"NCT02170675","phase":"PHASE1","title":"Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT01259115","phase":"PHASE1","title":"Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole","status":"COMPLETED","sponsor":"Purdue Pharma LP","startDate":"2002-10","conditions":"Healthy","enrollment":20},{"nctId":"NCT01153711","phase":"PHASE1","title":"Relative Bioavailability of of Olodaterol and Ketoconazole","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-05","conditions":"Healthy, Pulmonary Disease, Chronic Obstructive","enrollment":32},{"nctId":"NCT01637636","phase":"PHASE1","title":"Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2012-06","conditions":"Healthy","enrollment":48},{"nctId":"NCT01932320","phase":"PHASE1","title":"A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2010-02","conditions":"Healthy","enrollment":36},{"nctId":"NCT01707940","phase":"PHASE1","title":"Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT00948662","phase":"PHASE1","title":"Study Evaluating The Safety And Tolerability Of Administration Of Single Oral Doses Of SAM-760 To Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09","conditions":"Healthy","enrollment":124},{"nctId":"NCT01588782","phase":"PHASE1","title":"A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-01","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT00212095","phase":"PHASE2","title":"Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer","status":"COMPLETED","sponsor":"National University Hospital, Singapore","startDate":"2005-06","conditions":"Metastatic Breast Cancer","enrollment":30},{"nctId":"NCT01205230","phase":"PHASE4","title":"VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Cancer","enrollment":34},{"nctId":"NCT00419783","phase":"PHASE1","title":"A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-08","conditions":"Healthy","enrollment":30},{"nctId":"NCT01548170","phase":"PHASE1","title":"To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2011-04","conditions":"Cancer","enrollment":12},{"nctId":"NCT01473069","phase":"PHASE1","title":"Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects","status":"TERMINATED","sponsor":"Akros Pharma Inc.","startDate":"2010-03","conditions":"Healthy","enrollment":41},{"nctId":"NCT01149785","phase":"PHASE1","title":"Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-07","conditions":"Healthy","enrollment":15},{"nctId":"NCT00162214","phase":"PHASE1","title":"Study of Dasatinib in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2005-08","conditions":"Tumors","enrollment":60},{"nctId":"NCT00750425","phase":"PHASE1","title":"Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-08","conditions":"Advanced Solid Tumors","enrollment":46},{"nctId":"NCT01202240","phase":"PHASE1","title":"Effect Of Ketoconazole On The Pharmacokinetics Of Tasocitinib (CP-690,550) In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Healthy","enrollment":12},{"nctId":"NCT00860275","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-04","conditions":"Alzheimer Disease","enrollment":30},{"nctId":"NCT00707551","phase":"PHASE1","title":"An Interaction Study of Ketoconazole/Verapamil Versus AZD1305","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-07","conditions":"Healthy","enrollment":27},{"nctId":"NCT00812344","phase":"PHASE1","title":"Effect of Ketoconazole on Biliary Excretion of AZD0837","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT00890318","phase":"PHASE1","title":"A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C","status":"COMPLETED","sponsor":"Abbott","startDate":"2009-04","conditions":"HCV Infection","enrollment":32},{"nctId":"NCT00768690","phase":"PHASE1","title":"A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-10","conditions":"HCV Infection","enrollment":45},{"nctId":"NCT00931073","phase":"PHASE1","title":"A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-07","conditions":"Alzheimer's Disease, Huntington's Disease","enrollment":24},{"nctId":"NCT00983216","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Colchicine and Ketoconazole","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2008-07","conditions":"Pharmacokinetics","enrollment":24},{"nctId":"NCT00494663","phase":"PHASE2","title":"A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes","status":"TERMINATED","sponsor":"DiObex","startDate":"2007-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT00468689","phase":"PHASE1","title":"Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Osteoporosis","enrollment":15},{"nctId":"NCT00410501","phase":"PHASE1","title":"Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Healthy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"ASTHENIA"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CUSHING'S SYNDROME"},{"count":1,"reaction":"DISEASE PROGRESSION"},{"count":1,"reaction":"DIZZINESS"}],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nizoral"],"phase":"phase_2","status":"active","brandName":"Ketoconazole tablet","genericName":"Ketoconazole tablet","companyName":"Purdue Pharma LP","companyId":"purdue-pharma-lp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ketoconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a vital component of fungal cell membranes, by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase. Used for Treatment of systemic fungal infections such as blastomycosis, coccidioidomycosis, histoplasmosis, and aspergillosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}